Genotype-Phenotype Interactions in the Myeloproliferative Neoplasms

Hematology/Oncology Clinics of North America

Volumn 26, Issue 5, 2012, Pages 993-1015

  Godfrey, Anna L ^a,b   Green, Anthony R ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Hematopoiesis; JAK2; MPL; Myeloproliferative neoplasms

Indexed keywords

CYTOKINE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; JANUS KINASE 2; TRANSCRIPTION FACTOR EZH2;

ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; DISEASE ASSOCIATION; DISEASE SEVERITY; ERYTHROCYTOSIS; EXON; GENE INTERACTION; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HEMATOPOIETIC STEM CELL; HUMAN; MYELOID METAPLASIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTHEMIA;

GENOTYPE; HUMANS; JANUS KINASE 2; MUTATION; MYELOPROLIFERATIVE DISORDERS; PHENOTYPE; POLYCYTHEMIA VERA; PROGNOSIS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84866596022     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2012.07.003     Document Type: Review

References (169)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951, 6(4):372-375.
2. James C., Ugo V., Le Couedic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434(7037):1144-1148.
3. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365(9464):1054-1061.
4. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7(4):387-397.
5. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352(17):1779-1790.
6. Jamieson C.H., Gotlib J., Durocher J.A., et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci U S A 2006, 103(16):6224-6229.
7. Delhommeau F., Dupont S., Tonetti C., et al. Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood 2007, 109(1):71-77.
8. Ishii T., Bruno E., Hoffman R., et al. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood 2006, 108(9):3128-3134.
9. Dupont S., Masse A., James C., et al. The JAK2 V617F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood 2007, 110(3):1013-1021.
10. Saharinen P., Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 2002, 277(49):47954-47963.
11. Sanz A., Ungureanu D., Pekkala T., et al. Analysis of Jak2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutation. PLoS One 2011, 6(4):e18522.
12. Zaleskas V.M., Krause D.S., Lazarides K., et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS One 2006, 1:e18.
13. Kamishimoto J., Tago K., Kasahara T., et al. Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation. Cell Signal 2011, 23(5):849-856.
14. Funakoshi-Tago M., Tago K., Abe M., et al. STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant. J Biol Chem 2010, 285(8):5296-5307.
15. Yan D., Hutchison R.E., Mohi G. Critical requirement for Stat5 in a mouse model of polycythemia vera. Blood 2011, 119(15):3539-3549.
16. Walz C., Ahmed W., Lazarides K., et al. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood 2012, 119(15):3550-3560.
17. Garcon L., Rivat C., James C., et al. Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells. Blood 2006, 108(5):1551-1554.
18. Wardrop D., Steensma D.P. Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category?. Br J Haematol 2009, 144(6):809-817.
19. Levine R.L., Loriaux M., Huntly B.J., et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005, 106(10):3377-3379.
20. Jones A.V., Kreil S., Zoi K., et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005, 106(6):2162-2168.
21. Rane S.G., Reddy E.P. Janus kinases: components of multiple signaling pathways. Oncogene 2000, 19(49):5662-5679.
22. Campbell P.J., Scott L.M., Buck G., et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005, 366(9501):1945-1953.
23. Antonioli E., Guglielmelli P., Pancrazzi A., et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005, 19(10):1847-1849.
24. Wolanskyj A.P., Lasho T.L., Schwager S.M., et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005, 131(2):208-213.
25. Cheung B., Radia D., Pantelidis P., et al. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol 2006, 132(2):244-245.
26. Kittur J., Knudson R.A., Lasho T.L., et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 2007, 109(11):2279-2284.
27. Dahabreh I.J., Zoi K., Giannouli S., et al. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res 2009, 33(1):67-73.
28. Tefferi A., Lasho T.L., Schwager S.M., et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 2006, 106(3):631-635.
29. Vannucchi A.M., Antonioli E., Guglielmelli P., et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007, 110(3):840-846.
30. Vannucchi A.M., Antonioli E., Guglielmelli P., et al. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008, 22(7):1299-1307.
31. Vannucchi A.M., Antonioli E., Guglielmelli P., et al. Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden. Leukemia 2007, 21(9):1952-1959.
32. Passamonti F., Rumi E., Pietra D., et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010, 24(9):1574-1579.
33. Silver R.T., Vandris K., Wang Y.L., et al. JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leuk Res 2011, 35(2):177-182.
34. Lippert E., Boissinot M., Kralovics R., et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006, 108(6):1865-1867.
35. Tefferi A., Strand J.J., Lasho T.L., et al. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia 2007, 21(9):2074-2075.
36. Moliterno A.R., Williams D.M., Rogers O., et al. Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. Exp Hematol 2008, 36(11):1480-1486.
37. Carobbio A., Finazzi G., Antonioli E., et al. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol 2009, 37(9):1016-1021.
38. Antonioli E., Guglielmelli P., Poli G., et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 2008, 93(1):41-48.
39. Larsen T.S., Pallisgaard N., Moller M.B., et al. Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow. Leukemia 2008, 22(1):194-195.
40. Scott L.M., Scott M.A., Campbell P.J., et al. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 2006, 108(7):2435-2437.
41. Larsen T.S., Pallisgaard N., Moller M.B., et al. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis-impact on disease phenotype. Eur J Haematol 2007, 79(6):508-515.
42. Pardanani A., Lasho T.L., Finke C., et al. Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. Stem Cells 2007, 25(9):2358-2362.
43. Stein B.L., Williams D.M., Wang N.Y., et al. Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. Haematologica 2010, 95(7):1090-1097.
44. Godfrey A.L., Chen E., Pagano F., et al. JAK2V617F-homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. Blood 2012, [Epub ahead of print].
45. Gaikwad A., Nussenzveig R., Liu E., et al. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele. Exp Hematol 2007, 35(4):587-595.
46. Anand S., Stedham F., Beer P., et al. Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms. Blood 2011, 118(1):177-181.
47. Li J., Kent D.G., Chen E., et al. Mouse models of myeloproliferative neoplasms: JAK of all grades. Dis Model Mech 2011, 4(3):311-317.
48. Wernig G., Mercher T., Okabe R., et al. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006, 107(11):4274-4281.
49. Bumm T.G., Elsea C., Corbin A.S., et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res 2006, 66(23):11156-11165.
50. Lacout C., Pisani D.F., Tulliez M., et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006, 108(5):1652-1660.
51. Shide K., Shimoda H.K., Kumano T., et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia 2008, 22(1):87-95.
52. Xing S., Wanting T.H., Zhao W., et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 2008, 111(10):5109-5117.
53. Tiedt R., Hao-Shen H., Sobas M.A., et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008, 111(8):3931-3940.
54. Mullally A., Lane S.W., Ball B., et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 2010, 17(6):584-596.
55. Marty C., Lacout C., Martin A., et al. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood 2010, 116(5):783-787.
56. Akada H., Yan D., Zou H., et al. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 2010, 115(17):3589-3597.
57. Li J., Spensberger D., Ahn J.S., et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood 2010, 116(9):1528-1538.
58. Kralovics R., Teo S.S., Buser A.S., et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood 2005, 106(10):3374-3376.
59. Pellagatti A., Vetrie D., Langford C.F., et al. Gene expression profiling in polycythemia vera using cDNA microarray technology. Cancer Res 2003, 63(14):3940-3944.
60. Chen E., Beer P.A., Godfrey A.L., et al. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell 2010, 18(5):524-535.
61. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005, 5(5):375-386.
62. Scott L.M., Tong W., Levine R.L., et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007, 356(5):459-468.
63. Pietra D., Li S., Brisci A., et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008, 111(3):1686-1689.
64. Schnittger S., Bacher U., Haferlach C., et al. Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera. Haematologica 2009, 94(3):414-418.
65. Li S., Kralovics R., De Libero G., et al. Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. Blood 2008, 111(7):3863-3866.
66. Pardanani A., Lasho T.L., Finke C., et al. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007, 21(9):1960-1963.
67. Siemiatkowska A., Bieniaszewska M., Hellmann A., et al. JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms. Leuk Res 2010, 34(3):387-389.
68. Yeh Y.M., Chen Y.L., Cheng H.Y., et al. High percentage of JAK2 exon 12 mutation in Asian patients with polycythemia vera. Am J Clin Pathol 2010, 134(2):266-270.
69. Martinez-Aviles L., Besses C., Alvarez-Larran A., et al. JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis. Haematologica 2007, 92(12):1717-1718.
70. Kouroupi E., Zoi K., Parquet N., et al. Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F-negative polycythaemia vera patients. Br J Haematol 2008, 142(4):676-679.
71. Williams D.M., Kim A.H., Rogers O., et al. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. Exp Hematol 2007, 35(11):1641-1646.
72. Percy M.J., Scott L.M., Erber W.N., et al. The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels. Haematologica 2007, 92(12):1607-1614.
73. Ormazabal C., Hurtado C., Aranaz P., et al. Low frequency of JAK2 exon 12 mutations in classic and atypical CMPDs. Leuk Res 2008, 32(9):1485-1487.
74. Albiero E., Madeo D., Ruggeri M., et al. Loss of the JAK2 intramolecular auto-inhibition mechanism is predicted by structural modelling of a novel exon 12 insertion mutation in a case of idiopathic erythrocytosis. Br J Haematol 2008, 142(6):986-990.
75. Butcher C.M., Hahn U., To L.B., et al. Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients. Leukemia 2008, 22(4):870-873.
76. Colaizzo D., Amitrano L., Tiscia G.L., et al. A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis. Blood 2007, 110(7):2768-2769.
77. Passamonti F., Elena C., Schnittger S., et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood 2011, 117(10):2813-2816.
78. Bernardi M., Ruggeri M., Albiero E., et al. Isolated erythrocytosis in V617F negative patients with JAK2 exon 12 mutations: report of a new mutation. Am J Hematol 2009, 84(4):258-260.
79. Scott L.M., Beer P.A., Bench A.J., et al. Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera. Br J Haematol 2007, 139(3):511-512.
80. Beer P.A., Erber W.N., Campbell P.J., et al. How I treat essential thrombocythemia. Blood 2011, 117(5):1472-1482.
81. Plo I., Nakatake M., Malivert L., et al. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood 2008, 112(4):1402-1412.
82. Zhao R., Follows G.A., Beer P.A., et al. Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders. N Engl J Med 2008, 359(26):2778-2789.
83. Campbell P.J., Baxter E.J., Beer P.A., et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 2006, 108(10):3548-3555.
84. Beer P.A., Delhommeau F., LeCouedic J.P., et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 2010, 115(14):2891-2900.
85. Pikman Y., Lee B.H., Mercher T., et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006, 3(7):e270.
86. Beer P.A., Campbell P.J., Scott L.M., et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008, 112(1):141-149.
87. Chaligne R., Tonetti C., Besancenot R., et al. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia 2008, 22(8):1557-1566.
88. Pardanani A.D., Levine R.L., Lasho T., et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006, 108(10):3472-3476.
89. Boyd E.M., Bench A.J., Goday-Fernandez A., et al. Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. Br J Haematol 2010, 149(2):250-257.
90. Schnittger S., Bacher U., Haferlach C., et al. Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis. Haematologica 2009, 94(1):141-144.
91. Ding J., Komatsu H., Wakita A., et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 2004, 103(11):4198-4200.
92. Teofili L., Giona F., Martini M., et al. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol 2007, 25(9):1048-1053.
93. Pietra D., Brisci A., Rumi E., et al. Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms. Haematologica 2011, 96(4):607-611.
94. Kawamata N., Ogawa S., Yamamoto G., et al. Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray. Exp Hematol 2008, 36(11):1471-1479.
95. Vannucchi A.M., Antonioli E., Guglielmelli P., et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 2008, 112(3):844-847.
96. Guglielmelli P., Pancrazzi A., Bergamaschi G., et al. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol 2007, 137(3):244-247.
97. Beer P.A., Jones A.V., Bench A.J., et al. Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones. Br J Haematol 2009, 144(6):904-908.
98. Pecquet C., Staerk J., Chaligne R., et al. Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. Blood 2010, 115(5):1037-1048.
99. Chaligne R., James C., Tonetti C., et al. Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis. Blood 2007, 110(10):3735-3743.
100. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010, 24(6):1128-1138.
101. Vainchenker W., Delhommeau F., Constantinescu S.N., et al. New mutations and pathogenesis of myeloproliferative neoplasms. Blood 2011, 118(7):1723-1735.
102. Delhommeau F., Dupont S., Della Valle V., et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 360(22):2289-2301.
103. Tefferi A., Pardanani A., Lim K.H., et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009, 23(5):905-911.
104. Abdel-Wahab O., Mullally A., Hedvat C., et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009, 114(1):144-147.
105. Couronne L., Lippert E., Andrieux J., et al. Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias. Leukemia 2010, 24(1):201-203.
106. Abdel-Wahab O., Manshouri T., Patel J., et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010, 70(2):447-452.
107. Tefferi A., Lim K.H., Abdel-Wahab O., et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009, 23(7):1343-1345.
108. Jankowska A.M., Szpurka H., Tiu R.V., et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009, 113(25):6403-6410.
109. Kosmider O., Gelsi-Boyer V., Ciudad M., et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 2009, 94(12):1676-1681.
110. Nibourel O., Kosmider O., Cheok M., et al. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood 2010, 116(7):1132-1135.
111. Quivoron C., Couronne L., Della Valle V., et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer cell 2011, 20(1):25-38.
112. Chou W.C., Chou S.C., Liu C.Y., et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood 2011, 118(14):3803-3810.
113. Ko M., Huang Y., Jankowska A.M., et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010, 468(7325):839-843.
114. Ko M., Bandukwala H.S., An J., et al. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci U S A 2011, 108(35):14566-14571.
115. Li Z., Cai X., Cai C.L., et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011, 118(17):4509-4518.
116. Moran-Crusio K., Reavie L., Shih A., et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011, 20(1):11-24.
117. Pronier E., Almire C., Mokrani H., et al. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood 2011, 118(9):2551-2555.
118. Schaub F.X., Looser R., Li S., et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 2010, 115(10):2003-2007.
119. Vire E., Brenner C., Deplus R., et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006, 439(7078):871-874.
120. Ernst T., Chase A.J., Score J., et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010, 42(8):722-726.
121. Guglielmelli P., Biamonte F., Score J., et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood 2011, 118(19):5227-5234.
122. Abdel-Wahab O., Pardanani A., Patel J., et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 2011, 25(7):1200-1202.
123. Nikoloski G., Langemeijer S.M., Kuiper R.P., et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010, 42(8):665-667.
124. Jankowska A.M., Makishima H., Tiu R.V., et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 2011, 118(14):3932-3941.
125. Makishima H., Jankowska A.M., Tiu R.V., et al. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia 2010, 24(10):1799-1804.
126. Scheuermann J.C., de Ayala Alonso A.G., Oktaba K., et al. Histone H2A deubiquitinase activity of the polycomb repressive complex PR-DUB. Nature 2010, 465(7295):243-247.
127. Carbuccia N., Murati A., Trouplin V., et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009, 23(11):2183-2186.
128. Gelsi-Boyer V., Trouplin V., Adelaide J., et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009, 145(6):788-800.
129. Gelsi-Boyer V., Trouplin V., Roquain J., et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol 2010, 151(4):365-375.
130. Thol F., Friesen I., Damm F., et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol 2011, 29(18):2499-2506.
131. Pratcorona M., Abbas S., Sanders M., et al. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. Haematologica 2012, 97(3):388-392.
132. Martinez-Aviles L., Besses C., Alvarez-Larran A., et al. TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms. Ann Hematol 2012, 91(4):533-541.
133. Stein B.L., Williams D.M., O'Keefe C., et al. Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. Haematologica 2011, 96(10):1462-1469.
134. Mardis E.R., Ding L., Dooling D.J., et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009, 361(11):1058-1066.
135. Paschka P., Schlenk R.F., Gaidzik V.I., et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010, 28(22):3636-3643.
136. Schnittger S., Haferlach C., Ulke M., et al. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood 2010, 116(25):5486-5496.
137. Ward P.S., Patel J., Wise D.R., et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17(3):225-234.
138. Pardanani A., Lasho T.L., Finke C.M., et al. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia 2010, 24(6):1146-1151.
139. Tefferi A., Lasho T.L., Abdel-Wahab O., et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010, 24(7):1302-1309.
140. Thol F., Weissinger E.M., Krauter J., et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 2010, 95(10):1668-1674.
141. Kosmider O., Gelsi-Boyer V., Slama L., et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 2010, 24(5):1094-1096.
142. Tefferi A., Jimma T., Sulai N.H., et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 2012, 26(3):475-480.
143. Green A., Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 2010, 362(4):369-370.
144. Dang L., White D.W., Gross S., et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462(7274):739-744.
145. Zhao S., Lin Y., Xu W., et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009, 324(5924):261-265.
146. Figueroa M.E., Abdel-Wahab O., Lu C., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18(6):553-567.
147. Ley T.J., Ding L., Walter M.J., et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010, 363(25):2424-2433.
148. Walter M.J., Ding L., Shen D., et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011, 25(7):1153-1158.
149. Thol F., Winschel C., Ludeking A., et al. Rare occurrence of DNMT3A mutations in myelodysplastic syndromes. Haematologica 2011, 96(12):1870-1873.
150. Stegelmann F., Bullinger L., Schlenk R.F., et al. DNMT3A mutations in myeloproliferative neoplasms. Leukemia 2011, 25(7):1217-1219.
151. Abdel-Wahab O., Pardanani A., Rampal R., et al. DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia 2011, 25(7):1219-1220.
152. Bersenev A., Wu C., Balcerek J., et al. Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2. J Clin Invest 2008, 118(8):2832-2844.
153. Gery S., Gueller S., Chumakova K., et al. Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders. Blood 2007, 110(9):3360-3364.
154. Tong W., Lodish H.F. Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis. J Exp Med 2004, 200(5):569-580.
155. Tong W., Zhang J., Lodish H.F. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood 2005, 105(12):4604-4612.
156. Velazquez L., Cheng A.M., Fleming H.E., et al. Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. J Exp Med 2002, 195(12):1599-1611.
157. Takaki S., Morita H., Tezuka Y., et al. Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein, Lnk. J Exp Med 2002, 195(2):151-160.
158. Oh S.T., Simonds E.F., Jones C., et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010, 116(6):988-992.
159. Lasho T.L., Pardanani A., Tefferi A. LNK mutations in JAK2 mutation-negative erythrocytosis. N Engl J Med 2010, 363(12):1189-1190.
160. Pardanani A., Lasho T., Finke C., et al. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia 2010, 24(10):1713-1718.
161. Ogawa S., Sanada M., Shih L.Y., et al. Gain-of-function c-CBL mutations associated with uniparental disomy of 11q in myeloid neoplasms. Cell Cycle 2010, 9(6):1051-1056.
162. Bacher U., Haferlach C., Schnittger S., et al. Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies. Ann Hematol 2010, 89(7):643-652.
163. Sargin B., Choudhary C., Crosetto N., et al. Flt3-dependent transformation by inactivating c-Cbl mutations in AML. Blood 2007, 110(3):1004-1012.
164. Caligiuri M.A., Briesewitz R., Yu J., et al. Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. Blood 2007, 110(3):1022-1024.
165. Grand F.H., Hidalgo-Curtis C.E., Ernst T., et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009, 113(24):6182-6192.
166. Sanada M., Suzuki T., Shih L.Y., et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 2009, 460(7257):904-908.
167. Makishima H., Cazzolli H., Szpurka H., et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol 2009, 27(36):6109-6116.
168. Kohlmann A., Grossmann V., Klein H.U., et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 2010, 28(24):3858-3865.
169. Beer P.A., Ortmann C.A., Stegelmann F., et al. Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms. Haematologica 2010, 95(12):2153-2156.